Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
NCT04572854Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- PEGylated Peptides
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (2 arms), sponsored by Apellis Pharmaceuticals. Primary endpoint: Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at 12 weeks. Started Sep 2021; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT04572854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572854.